About Crossbow Therapeutics
Crossbow Therapeutics is a private company based in Cambridge, Massachusetts, incorporated in 2021 in Delaware. It has reported $67,818,164 raised in two offerings on Form D since April 2023. Its chief executive is Briggs Morrison.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Sep 17, 2025 | Sep 30, 2025 | $30,250,000of $80.0M target | 17 | $1.7M | EquityRule 506(b) | Form D ↗ |
| Mar 29, 2023 | Apr 12, 2023 | $37,568,164of $80.0M target | 15 | $2.5M | EquityRule 506(b) | Form D ↗ |
| Total, two offerings | $67,818,164 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Crossbow Therapeutics's Form D filed Sep 30, 2025.
AN
Alexander Nolte
Executive officer
Alexandra Cantley
Director
Also a director at Auron Therapeutics, Cirrus Therapeutics and EpiBiologics.
DW
Dmitri Wiederschain
Executive officer
SA
Sakae Asanuma
Director
CB
Charles Baum
Director
Briggs Morrison
Chief Executive Officer and director
Also a director at Auron Therapeutics and Reunion Neuroscience.
IM
Irena Melnikova
Director
AL
TF
Earlier filings also listed Geraldine Paulus (executive officer, last listed Apr 2023).